Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule product candidates for the treatment of inflammatory diseases, cancer, and viral diseases in the United States. Its products include R112, a Phase II clinical trial completed product, which would be used for the treatment of allergic rhinitis; R788, Phase II clinical trial product, for the treatment of rheumatoid arthritis and thrombocytopenia; and R763, a Phase I clinical trial product, for the treatment of oncology. The company has collaborations agreements with Janssen Pharmaceutica N.V., Pfizer, Inc., Novartis Pharma AG, Daiichi Pharmaceuticals Co., Ltd.,...